AAdvantage Executive vs. Globe: Which is best for AA fans?

I have covered two bankruptcy stories before. Not from the usual angle of what happened and why; For each, I dug deep to see who could win from the wreckage.

gave The story of Magellan Aerospace led to me Homet. gave IKEA store closures Pointed to me target. Focus Factor maker Synergy CHC Corp. This week's Chapter 11 filing points me to Reckitt Benckiser (RBGLY).

Synergy CHC filed for bankruptcy in the US Bankruptcy Court for the District of Columbia on September 4, 2026. The Street Reported

Costco told the company in July that it would discontinue Focus Factor products after a 16-year relationship. Did you see that one decision? That cost Synergy about 58% of its 2025 total net income, accelerated $18.9 million in debt to its lender, and made Chapter 11 inevitable.

RBGLY currently trades at $14, down 10.62% year-to-date Yahoo Finance.

How 58% Revenue Concentration Becomes a Fatal Point of Failure

The Synergy CHC situation shows how quickly retail concentration can become a threat. Focus Factor is an active beverage brand with a 25-year legacy, enjoying established distribution in the US, Canada, and Mexico, and distributing to Walmart, Walgreens, Amazon, and BJ's.

The company is a brain supplement with vitamins, minerals, and neuronutrients. It has the “#1 Pharmacist Recommended” claim from the 2025-2026 US Pharmacy Times survey for memory support. Once Costco made its decision, none of that mattered.

More retail:

"Costco accounted for approximately 58 percent of the company's net revenue during the fiscal year ending December 31, 2025." SEC Filings stated that "the Company expects Costco's decision to have a material adverse effect on the Company's business, results of operations, liquidity, and financial condition."

Costco has not given a public reason for dropping the brand. It was not needed. It's a retailer that moves products in bulk, and it decided on its vendor for whatever reason.

The $18.9 million debt rush that followed confirmed that Synergy had no financial cushion to survive even a temporary revenue disruption of this magnitude.

Why I think Racquet's Neureva is the clear beneficiary.

Three structural advantages make the racket the clear winner.

Nureva is already in Costco's system. Neurova Brain Supplement Original (50 Capsules) is currently retailing. Costco for $43.99. Reckitt doesn't need to win vendor slots or meet Costco's notorious supplier requirements. It is already approved, integrated and sold. It is practically easier to measure volume within an existing supplier relationship.
Reckitt's product portfolio fits neatly into where Costco wants to go. Costco members are drawn to established brands and research-backed premium wellness products. The racket is spreading aggressively. NerivaWith products including Nureva Plus, Nureva Ultra, and Neurova Memory 3D. I see these premium formulations far superior to Costco's legacy Focus Factor lineup in its push toward higher-margin health solutions.
Regulatory history also matters. Faced with the focus factor FTC settlements and consumer class action lawsuits challenging its efficacy claims. Racket Neurova's marketing is built around clinically studied ingredients and GMO-free formulations.

After dropping a brand with this compliance history, Costco's buyer relationships would naturally favor an institutional, publicly traded consumer health company with a clean regulatory record.

Neureva Brain Supplement Original (50 capsules) currently retails for $43.99 at Costco. BearPhotos Via Shutterstock

Reckitt business picture and what H1 2026 results show.

The business picture is important for investors whether RBGLY represents an opportunity at $14.00 and down 10.62% year-to-date. While it is primarily listed on the London Stock Exchange (RKT), it is highly visible to US market investors through its American Depositary Receipts (ADRs) on the over-the-counter market under the ticker RBGLY.

According to Racket, the results for the half-year 2026 (H1 2026) showed a 2.7% increase in net income as core Racket, which only increased to 4.2% in the second quarter. Income statement.

The gross profit margin for Core Rect was 60.9%. Adjusted operating profit margin was 24.8%. Free cash flow in the first half was £419 million. During this period around £3 billion was returned to shareholders through dividends and buybacks. Q2 earnings call.

RELATED: Loss of Costco deal helps push beverage brand into Chapter 11

Reckitt also announced a 5% increase in its interim dividend along with an additional £500 million share buyback. Full-year 2026 guidance calls for net revenue growth of 4% to 5% across the board.

A special dividend was also paid in February 2026 after completion of Distribution of Essential Home BusinessReturning excess capital to shareholders.

Macrotrends' The figures show RBGLY with a dividend yield of 4.6% at current prices, with a most recent dividend of $0.64 per share.

The valuation picture is also fair: a P/E of 11.36 and a forward P/E of 14.24 for a company with a 60.9% gross margin, a growing consumer health platform, and a direct competitive beneficiary of the demise of its largest mental health competitor.

What to look forward to at Costco

Synergy CHC built a strong brand on a structurally weak foundation. A concentration risk was seen long before bankruptcy filings. And then when Costco moved, math became inevitable.

I think Racket has what it takes. Costco has the shelf presence, regulatory credibility, supply chain, and product portfolio to absorb this demand without adding structural risk.

All of this and more is likely to translate into RBGLY's financial results, depending on how aggressively Costco expands Neuriva along with overall product development.

RELATED: Costco asks members to help improve stores

This story was originally published by The Street On September 15, 2026, where it was first published. Investment Add section TheStreet as a. Preferred Source by clicking here.